Payment overview · 2025
General Payments
$8,590.40
42 reported records · 10 companies
Healthcare provider profile · identity verified
Christopher C. Case, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Endocrinology, Diabetes & Metabolism · JEFFERSON CITY, MO · NPI 1871552794
Verified facts
What the public records show
CMS Open Payments records show Christopher C. Case, M.D. received $8,590.40 in general payments during 2025 across 42 reported records.
Novo Nordisk Inc accounted for 97.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Korlym, Ozempic, Rybelsus.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Prolia by this doctor in 2024.
Corcept Therapeutics reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Korlym as an associated drug or biological on 56316 records involving 19205 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Korlym by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Fiasp as an associated drug or biological on 15 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Fiasp by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 724 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Rybelsus by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Tresiba as an associated drug or biological on 415 records involving 264 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Tresiba by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $8,354.11 | 97.2% | 30 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $53.40 | 0.6% | 3 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $37.31 | 0.4% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $28.66 | 0.3% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$26.36 | 0.3% | 1 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $19.02 | 0.2% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $18.50 | 0.2% | 1 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $18.29 | 0.2% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $18.05 | 0.2% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $16.70 | 0.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $5,254.50 | 3 |
| Consulting Fee | $2,790.00 | 2 |
| Food and Beverage | $513.63 | 36 |
| Education | $32.27 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $5,479.14 | 18 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $84.97 | 10 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $81.12 | 10 | 2025 |
Source payment records
|
|||||
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $53.40 | 3 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $37.31 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $28.66 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $28.66 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $28.66 | 1 | 2025 |
Source payment records
|
|||||
| KYPHON EXPRESS II KYPHOPAK TRAY Normalized: kyphon express ii kyphopak tray |
Device | Medtronic, Inc. | $26.36 | 1 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $19.02 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $18.50 | 1 | 2025 |
Source payment records
|
|||||
| JATENZO Normalized: jatenzo |
Drug | TOLMAR, INC. | $18.29 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $18.05 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $16.70 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Korlym korlym |
2025 | Korlym | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 724 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 86 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Corcept Therapeutics Exact reporting entity; no affiliate inference |
2025 | Korlym open payments reported associated product |
CMS Open Payments — General Payments 56316 supporting records · 19205 recipient NPIs · example record 1214133822 |
Korlym · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Fiasp open payments reported associated product |
CMS Open Payments — General Payments 15 supporting records · 15 recipient NPIs · example record 1188262936 |
Fiasp · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
724 | 176 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
86 | 19 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Tresiba open payments reported associated product |
CMS Open Payments — General Payments 415 supporting records · 264 recipient NPIs · example record 1188130328 |
Tresiba · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 1133 | 267 |
| Glimepiride | Glimepiride | 963 | 265 |
| Metformin Hcl | Metformin Hcl | 743 | 184 |
| Ozempic | Semaglutide | 724 | 176 |
| Pioglitazone Hcl | Pioglitazone Hcl | 664 | 189 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 446 | 125 |
| Mounjaro | Tirzepatide | 433 | 80 |
| Metformin Hcl Er | Metformin Hcl | 428 | 116 |
| Tresiba Flextouch U-200 | Insulin Degludec | 345 | 79 |
| Atorvastatin Calcium | Atorvastatin Calcium | 335 | 92 |
| Humalog Kwikpen U-100 | Insulin Lispro | 335 | 94 |
| Lisinopril | Lisinopril | 300 | 87 |
| Tresiba Flextouch U-100 | Insulin Degludec | 290 | 77 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 286 | 112 |
| Gabapentin | Gabapentin | 258 | 57 |
| Furosemide | Furosemide | 255 | 64 |
| Jardiance | Empagliflozin | 249 | 53 |
| Farxiga | Dapagliflozin Propanediol | 230 | 45 |
| Synthroid | Levothyroxine Sodium | 177 | 43 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 171 | 50 |
| Novolog Flexpen | Insulin Aspart | 160 | 56 |
| Glipizide | Glipizide | 155 | 40 |
| Hydrochlorothiazide | Hydrochlorothiazide | 153 | 43 |
| Glipizide Er | Glipizide | 151 | 31 |
| Duloxetine Hcl | Duloxetine Hcl | 148 | 30 |
| Methimazole | Methimazole | 148 | 39 |
| Omeprazole | Omeprazole | 148 | 36 |
| Pravastatin Sodium | Pravastatin Sodium | 148 | 41 |
| Simvastatin | Simvastatin | 143 | 38 |
| Amlodipine Besylate | Amlodipine Besylate | 129 | 38 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 129 | 29 |
| Losartan Potassium | Losartan Potassium | 124 | 34 |
| Pregabalin | Pregabalin | 102 | 26 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 102 | 24 |
| Testosterone Cypionate | Testosterone Cypionate | 100 | 19 |
| Liothyronine Sodium | Liothyronine Sodium | 96 | 18 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 95 | 19 |
| Potassium Chloride | Potassium Chloride | 95 | 22 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 94 | 40 |
| Alendronate Sodium | Alendronate Sodium | 92 | 26 |
| Np Thyroid | Thyroid,pork | 92 | 21 |
| Alprazolam | Alprazolam | 90 | 14 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 88 | 19 |
| Rybelsus | Semaglutide | 86 | 19 |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 82 | 28 |
| Zolpidem Tartrate | Zolpidem Tartrate | 81 | 19 |
| Humalog | Insulin Lispro | 80 | 23 |
| Pantoprazole Sodium | Pantoprazole Sodium | 78 | 20 |
| Trulicity | Dulaglutide | 76 | 16 |
| Humulin R U-500 Kwikpen | Insulin Regular, Human | 75 | 16 |
| Fenofibrate | Fenofibrate | 73 | 13 |
| Omnipod 5 Dexg7g6 Pods (Gen 5) | Insulin Pump Cart,auto,bt,g6/7 | 72 | 12 |
| Armour Thyroid | Thyroid,pork | 69 | 17 |
| Carvedilol | Carvedilol | 67 | 19 |
| Januvia | Sitagliptin Phosphate | 67 | 12 |
| Insulin Lispro | Insulin Lispro | 66 | 17 |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 65 | 21 |
| Tramadol Hcl | Tramadol Hcl | 65 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 64 | 13 |
| Levemir Flexpen | Insulin Detemir | 63 | 20 |
| Metoprolol Tartrate | Metoprolol Tartrate | 63 | 17 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 63 | 22 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 57 | 14 |
| Testosterone | Testosterone | 56 | 17 |
| Allopurinol | Allopurinol | 52 | 12 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 50 | suppressed |
| Techlite Pen Needle | Pen Needle, Diabetic | 49 | 23 |
| Diazepam | Diazepam | 48 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 47 | 12 |
| Clonazepam | Clonazepam | 46 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 46 | 14 |
| Ezetimibe | Ezetimibe | 46 | 15 |
| Metoprolol Succinate | Metoprolol Succinate | 45 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 44 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 43 | 14 |
| Tresiba | Insulin Degludec | 42 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 41 | 11 |
| Repatha Sureclick | Evolocumab | 41 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 39 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 39 | suppressed |
| Pioglitazone-Metformin | Pioglitazone Hcl/Metformin Hcl | 38 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 37 | suppressed |
| Atenolol | Atenolol | 36 | suppressed |
| Gemfibrozil | Gemfibrozil | 36 | suppressed |
| Invokana | Canagliflozin | 36 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 36 | suppressed |
| Fluconazole | Fluconazole | 35 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 35 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 35 | suppressed |
| Eliquis | Apixaban | 34 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 34 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 33 | 15 |
| Lorazepam | Lorazepam | 31 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Hydrocortisone | Hydrocortisone | 30 | suppressed |
| Spironolactone | Spironolactone | 30 | suppressed |
| Topiramate | Topiramate | 30 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 29 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 28 | suppressed |
| Valsartan | Valsartan | 28 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 27 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 27 | 15 |
| Icosapent Ethyl | Icosapent Ethyl | 27 | suppressed |
| Kerendia | Finerenone | 27 | suppressed |
| Lovastatin | Lovastatin | 26 | suppressed |
| Xultophy 100-3.6 | Insulin Degludec/Liraglutide | 26 | suppressed |
| Glyburide-Metformin Hcl | Glyburide/Metformin Hcl | 25 | suppressed |
| Insulin Degludec Pen (U-100) | Insulin Degludec | 25 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 24 | suppressed |
| Meloxicam | Meloxicam | 24 | suppressed |
| Byetta | Exenatide | 23 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 23 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Victoza 3-Pak | Liraglutide | 23 | suppressed |
| Calcitriol | Calcitriol | 22 | suppressed |
| Ibuprofen | Ibuprofen | 22 | suppressed |
| Easy Touch Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Sure Comfort Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Azithromycin | Azithromycin | 20 | 15 |
| Novolog | Insulin Aspart | 20 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 20 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 19 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 19 | suppressed |
| Tradjenta | Linagliptin | 19 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 19 | suppressed |
| Estradiol | Estradiol | 18 | suppressed |
| Lyumjev Kwikpen U-100 | Insulin Lispro-Aabc | 18 | suppressed |
| Prednisone | Prednisone | 18 | suppressed |
| Repaglinide | Repaglinide | 18 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 17 | suppressed |
| Celecoxib | Celecoxib | 17 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Famotidine | Famotidine | 17 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 17 | suppressed |
| Insulin Degludec Pen (U-200) | Insulin Degludec | 17 | suppressed |
| Korlym | Mifepristone | 17 | suppressed |
| Prolia | Denosumab | 17 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 17 | suppressed |
| Cabergoline | Cabergoline | 16 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 16 | 11 |
| Insulin Syringe | Syring-Needl,disp,insul,0.3 Ml | 16 | suppressed |
| Ramelteon | Ramelteon | 16 | suppressed |
| Temazepam | Temazepam | 16 | suppressed |
| Vascepa | Icosapent Ethyl | 16 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 15 | suppressed |
| Propylthiouracil | Propylthiouracil | 15 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 15 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 14 | suppressed |
| Novofine 32 | Pen Needle, Diabetic | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 14 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 14 | suppressed |
| Cilostazol | Cilostazol | 13 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 13 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 13 | suppressed |
| Insulin Aspart | Insulin Aspart | 13 | suppressed |
| Nabumetone | Nabumetone | 13 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 13 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 13 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Climara Pro | Estradiol/Levonorgestrel | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 12 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 11 | suppressed |
| Mirtazapine | Mirtazapine | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $8,590.40 · 42 records | Novo Nordisk Inc | ABRYSVO, COMIRNATY, FREESTYLE LIBRE 3, JATENZO, KYPHON EXPRESS II KYPHOPAK TRAY, Korlym, LEQVIO, Ozempic, PREVNAR 20, RECORLEV, REPATHA, Rybelsus, Tymlos, Wegovy | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Korlym play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error